TY - JOUR
T1 - Outcomes After Definitive Surgery for Spinal and Sacral Chordoma in 101 Patients Over 20 Years
AU - Xia, Yuanxuan
AU - Papali, Pritika
AU - Al-Mistarehi, Abdel Hameed
AU - Hansen, Landon J.
AU - Azad, Tej D.
AU - Ahmed, A. Karim
AU - Meyer, Christian
AU - Gross, John
AU - Khan, Majid
AU - Bettegowda, Chetan
AU - Mukherjee, Raj
AU - Witham, Timothy
AU - Bydon, Ali
AU - Theodore, Nicholas
AU - Wolinsky, Jean Paul
AU - Gokaslan, Ziya L
AU - Lo, Sheng-fu
AU - Sciubba, Daniel
AU - Lee, Sang Hun
AU - Redmond, Kristin J.
AU - Lubelski, Daniel
N1 - Publisher Copyright:
© Congress of Neurological Surgeons 2024. All rights reserved.
PY - 2025/3/1
Y1 - 2025/3/1
N2 - BACKGROUND AND OBJECTIVES: Spinal chordomas are primary bone tumors where surgery remains the primary treatment. However, their low incidence, lack of evidence, and late disease presentation make them challenging to manage. Here, we report the postoperative outcomes of a large cohort of patients after surgical resection, investigate predictors for overall survival (OS) and local recurrence-free survival (LRFS) times, and trend functional outcomes over multiple time periods. METHODS: Retrospective review of all patients followed for spinal chordoma at a quaternary spinal oncology center from 2003 to 2023 was included. Data were collected regarding demographics, preoperative and perioperative management, and follow-up since initial definitive surgery. Primary outcomes were OS and LRFS, whereas secondary outcomes were functional deficits. RESULTS: One hundred one patients had an average follow-up of 6.0 ± 4.2 years. At the time of census, 25/101 (24.8%) had experienced a recurrence and 10/101 (9.9%) had died. After surgery, patients experienced a significant decrease in pain over time, but rates of sensory deficits, weakness, and bowel/bladder dysfunction remained static. Tumors ≥100 cm3 (hazard ratio (HR) = 5.89, 95% CI 1.72-20.18, P = .005) and mobile spine chordomas (HR = 7.73, 95% CI 2.09-28.59, P = .002) are related to worse LRFS, whereas having neoadjuvant radiotherapy is associated with improved LRFS (HR = 0.09, 95% CI 0.01-0.88, P = .038). On the other hand, being age ≥65 years was associated with decreased OS (HR = 16.70, 95% CI 1.54-181.28, P = .021). CONCLUSION: Surgeons must often weigh the pros and cons of en bloc resection and sacrificing important but affected native tissues. Our findings can provide a benchmark for counseling patients with spinal chordoma. Tumors ≥100 cm3 appear to have a 5.89-times higher risk of recurrence, mobile spine chordomas have a 7.73 times higher risk, and neoadjuvant radiotherapy confers an 11.1 times lower risk for local recurrence. Patients age ≥65 years at surgery have a 16.70 times higher risk of mortality than those <65 years.
AB - BACKGROUND AND OBJECTIVES: Spinal chordomas are primary bone tumors where surgery remains the primary treatment. However, their low incidence, lack of evidence, and late disease presentation make them challenging to manage. Here, we report the postoperative outcomes of a large cohort of patients after surgical resection, investigate predictors for overall survival (OS) and local recurrence-free survival (LRFS) times, and trend functional outcomes over multiple time periods. METHODS: Retrospective review of all patients followed for spinal chordoma at a quaternary spinal oncology center from 2003 to 2023 was included. Data were collected regarding demographics, preoperative and perioperative management, and follow-up since initial definitive surgery. Primary outcomes were OS and LRFS, whereas secondary outcomes were functional deficits. RESULTS: One hundred one patients had an average follow-up of 6.0 ± 4.2 years. At the time of census, 25/101 (24.8%) had experienced a recurrence and 10/101 (9.9%) had died. After surgery, patients experienced a significant decrease in pain over time, but rates of sensory deficits, weakness, and bowel/bladder dysfunction remained static. Tumors ≥100 cm3 (hazard ratio (HR) = 5.89, 95% CI 1.72-20.18, P = .005) and mobile spine chordomas (HR = 7.73, 95% CI 2.09-28.59, P = .002) are related to worse LRFS, whereas having neoadjuvant radiotherapy is associated with improved LRFS (HR = 0.09, 95% CI 0.01-0.88, P = .038). On the other hand, being age ≥65 years was associated with decreased OS (HR = 16.70, 95% CI 1.54-181.28, P = .021). CONCLUSION: Surgeons must often weigh the pros and cons of en bloc resection and sacrificing important but affected native tissues. Our findings can provide a benchmark for counseling patients with spinal chordoma. Tumors ≥100 cm3 appear to have a 5.89-times higher risk of recurrence, mobile spine chordomas have a 7.73 times higher risk, and neoadjuvant radiotherapy confers an 11.1 times lower risk for local recurrence. Patients age ≥65 years at surgery have a 16.70 times higher risk of mortality than those <65 years.
KW - Enneking
KW - Outcomes
KW - Recurrence
KW - Spinal chordoma
KW - Surgery
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85218624097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85218624097&partnerID=8YFLogxK
U2 - 10.1227/neu.0000000000003130
DO - 10.1227/neu.0000000000003130
M3 - Article
C2 - 39101708
AN - SCOPUS:85218624097
SN - 0148-396X
VL - 96
SP - 494
EP - 504
JO - Neurosurgery
JF - Neurosurgery
IS - 3
ER -